BTX-9341 is a first-in-class, oral degrader of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated superiority to CDK4/6 inhibitors through potent and highly selective catalytic degradation of CDK4 and CDK6, robust inhibition of Cyclin E and CDK2 transcription, cell cycle arrest and ultimately superior in vivo efficacy in breast cancer xenografts. Beyond this increased efficacy potential, BTX-9341 is differentiated from CDK4/6 inhibitor approaches through the ability to overcome key resistance mechanisms that limit the impact of inhibitors in second line HR+/HER2- breast cancer (~70% have acquired resistance to CDK4/6 inhibitors). This exciting, new breast cancer therapy began a Phase 1 clinical trial in the third quarter of 2024.

Biotheryx has an ongoing research collaboration and license agreement with our pharmaceutical partner, Incyte, to discover and develop molecular glue degraders for historically undruggable novel targets.